Below is a link for a short article by Bill Balistreri about coffee and its potential benefit for fatty liver disease (“Hold the cream and sugar”) :
http://www.medscape.com/viewarticle/759379
Recent blog entry on coffee:
Below is a link for a short article by Bill Balistreri about coffee and its potential benefit for fatty liver disease (“Hold the cream and sugar”) :
http://www.medscape.com/viewarticle/759379
Recent blog entry on coffee:
A review and a study this month help delineate a strategy to lower the rate of HBV transmission (Clin Gastro Hepatol 2012; 10: 452-59 & 520-526). Overall, using HBIG and HBV vaccine within 12 hours of birth (followed by two additional doses of vaccines within 6-12 months) prevents about 95% of HBV transmission from HBsAg-positive mothers to their infants. This has made a huge difference. Yet, among mothers with high levels of viremia, HBV is still transmitted in 8-30%. As such, this review proposes an algorithm to reduce mother to child transmission (MTCT).
The key risk factor is HBV DNA levels >200,000 IU/mL; the most effective way to reduce transmission from highly-viremic mother to infancts is the use of antiviral therapy. The authors recommend that in addition to the usual preventive measures (HBIG/HBV vaccine within 12 hours of birth), that efforts to lower MTCT include use of either lamivudine (pregnancy category C), telbivudine (pregnancy category B), or tenofovir (pregnancy category B) at the 3rd trimester in the following:
In addition, elective C-section should be considered if HBV DNA >20 million IU/mL at full term.
The second citation refers to an open-label prospective study of 88 HBe-Ag positive women. All women had HBV DNA >6 log10 copies/mL and increased ALT. Telbivudine (600 mg/day) was administered to 53 women starting between 12 and 30 weeks gestation; there were 35 control patients who all received HBIG/HBV vaccine. In the treatment group, none of the infants developed HBV infection. In the control group, the transmission rate was 8.6%. No significant adverse effects were noted; specifically, no congenital malformations were noted.
Related blog entry/additional references:
Biliary atresia (BA) is often suspected among infants with prolonged jaundice. In fact, efforts have been underway for a long time to encourage fractionation of the bilirubin values to look for conjugated hyperbilirubinemia, especially in infants that remain jaundiced at three weeks of life. While this is still good advice, given the lack of success in implementation, there is good evidence that obtaining a fractionated bilirubin at any time point can help identify cholestasis associated with BA.
A recent article by Karpen et al (Pediatrics 2011; 128:. e1428 -e1433) indicates that direct bilirubin values are elevated beginning within the first one to two days in patients with BA. In their cohort of 61 BA subjects, 56% had newborn fractionated bilirubin values. Every BA patient had elevated direct bilirubin, on average 1.4 ± 0.43 mg/dL (normal <0.5) (compared with control patients: 0.19 ± 0.075 mg/dL, P < .0001). Also, another important finding was that early on the ratio of direct bilirubin to total bilirubin was normal in 79%; normally this ratios is ≤0.2. As such, all patients with increased direct bilirubin need to be followed closely.
Related blog entries:
With cholestasis in infancy, Bill Balistreri taught me that there were four potential emergencies:
Once these issues have been considered, then it is appropriate to start investigating the etiology of the cholestasis.
One of the more dramatic complications is intracranial hemorrhage (ICH). While ICH is a well-recognized complication of cholestasis in infancy, the long-term outcomes are not well-characterized. A report from Japan adds some insight (JPGN 2012; 54: 552-57).
Among a retrospective review of 83 infants with biliary atresia (BA) between 1979 to 2009, ICH occurred in 8% despite oral vitamin K prophylaxis (2 mg). The onset of ICH was between 47-76 days after birth and was prior to surgery. Coagulopathy was noted in all cases, which improved with vitamin K intravenously. Two infants required craniotomy. In 5 of 7 cases, neurologic sequelae were noted including developmental delay in three, epilepsy in one, and mild hemiparesis in two.
Additional references:
Serum ferritin levels were independently shown to be a risk factor for poor response to treatment in hepatitis C virus (HCV) infection (Hepatology 2012; 55: 1038-47). This article adds additional information to previous work which has shown that increased iron can be a comorbid factor in chronic viral hepatitis and other liver diseases.
This study used the Swiss Hepatitis C Cohort Study (SCCS) (n=3648). In this group, the success of treatment with pegylated interferon alpha and ribavirin were correlated with clinical and histological features.
Ferritin levels ≥ the sex-specific median values was one of the strongest pretreatment predictors of treatment failure (OR 0.45). It had a similar predictive effect as the IL28B genotype. In addition, higher ferritin levels were associated with severe liver fibrosis (OR 2.67) and steatosis (OR 2.29). For women the sex-specific median for ferritin level was 85 μg/L and for men it was 203 μg/L. The authors note that these cutoffs are quite close to the upper limits of normal of the general population (150 and 300 respectively).
Mechanistically, HCV interferes with the host’s iron metabolism leading to iron accumulation in the liver. Part of this is explained by down-regulation of hepcidin (Help with hepcidin). Part is due to ferritin acting as an acute phase reactant to inflammation. Ultimately, excess iron promotes liver inflammation, oxidative stress and mitochondrial dysfunction.
How important ferritin will be with newer therapies is not clear. It is likely that patients that are less responsive to dual therapy (pegylated interferon/ribavirin) will have poorer response as well to triple or quadruple therapies.
Additional references/previous related posts:
In hospital settings, there have been concerns about clinical care at night or weekends (see references below). At least with liver transplantation, 24/7 care appears to be the rule rather than the exception (Liver Transpl 2012; 18: 558-65).
Using the UNOS database, this study analyzed 94,768 transplants from 1987-2010. Survival rates at 30, 90, and 365 days for nighttime operations: 96%, 93%, and 86% respectively. For weekends, the respective rates were 95%, 92%, and 86%. These rates did not differ from weekday rates. Graft failure rates were modestly increased for weekend transplants at 365 days (HR 1.05, 95% confidence interval 1.01-1.11) but not for 30 days or 90 days. In addition, there was no difference in graft failure between nighttime and weekday transplantations.
Additional reference:
In a previous post (The Medical Pendulum and Gastroesophageal Reflux), I note that enthusiasm for proton pump inhibitors has started to wane. In addition, a significant number of reported of potential side effects were referenced. Another potential adverse effect is increasing the rate of spontaneous bacterial peritonitis (SBP) in patients with cirrhosis (Clin Gastroenterol Hepatol 2012; 10: 422-27).
This retrospective study examined 65 hospitalized cirrhotic patients with paracentesis-proven SBP between 2006-2009 and compared them to 65 contemporaneous hospitalized cirrhotic patients without SBP. Patients with SBP had a higher incidence of use of PPI within previous 7 days: 71% versus 42%. Of patients with SBP receiving PPI, the authors state that 68% did not have a documented indication for PPI use.
Additional references/previous posts:
From a pediatric hepatology viewpoint, I’ve always been concerned that scoring systems do not favor children. More data is now available relevant to this topic:
These articles and the editorials look at the model for end-stage liver disease (MELD) and exceptions for hepatocellular carcinoma (HCC) as well as the issue of split livers to expand the donor pool.
The goals of liver transplantation allocation is to distribute livers to minimize waiting list mortality, to distribute this valuable resource fairly, and to improve long-term outcomes. How are we doing?
With regard to HCC, the authors indicate that the current policy is increasing the number of individuals transplanted with this indication. Before MELD, 4.6% of all transplants were for candidates with HCC. Between 2002-2007, the number increased to 26%. This has dramatically improved the outcomes in this previously almost universally fatal disease.
But is the priority afforded by MELD priority unfair? From 2005-2009, Goldberg et al show that the rate of individuals with HCC removed from the waiting list because of death or disease progression was much lower than non-HCC patients: 4.2% vs. 11% (90-day waitlist outcome). Patients with HCC with exception points were 2.62 times less likely to die by waiting. Thus, the authors conclude that allocating 22 MELD points to HCC patients greatly overestimates 90-day mortality. Other conditions that receive 22 MELD points include candidates with hepatopulmonary syndrome, cholangiocarcinoma, cystic fibrosis, familial amyloidotic polyneuropathy, and portopulmonary syndrome.
Sepulveda et al performed a retrospective review of the experience from split liver transplantation in French adults. In their cohort of 36 patients who received extended right grafts from split livers, there were increased complications. Only 21 patients had a relatively easy postoperative course. Six patients required retransplantation. Overall survival rate was 84.2% and 77.7% at 1 and 5 years. Complications were related to ischemia of hepatic segment 4.
In the editorial, Riccardo Superina makes several important points:
Related blog posts:
Sarcopenia, fatigue, and nutrition in chronic liver disease
Additional references:
Criteria for autoimmune hepatitis (AIH) have been simplified over the last decade. The 2008 AIH criteria have a high sensitivity and specificity in children (Clin Gastroenterol Hepatol 2012; 10: 417-21).
This study examined 238 patients: 41 AIH patients and 197 non-AIH patients. Among these patients, 37 of the 41 AIH had sufficient data to calculate 2008 score using IgG or globulin & 40 of the 197 of the non-AIH had sufficient data. Within the 37 AIH patients, 31 had IgG levels; all 37 had either IgG or globulin. Similarly, among the 40 non-AIH patients, 26 had IgG levels available.
Among AIH patients: the 1999 criteria categorized 29 of 31 (94%) as definite AIH and 2 of 31 (6%) as probable AIH. The 2008 criteria: 25 definite AIH, 2 as probable AIH, and 4 were not identified as AIH; all four had fulminant hepatic failure (FHF).
The authors conclude that the simplified 2008 guidelines have high sensitivity/specificity and are easier to use. Patients with FHF require the 1999 criteria.
Autoantibodies:
ANA or SMA 1:40 1
ANA or SMA 1:80
or LKM
or SLA 1:40 2*
IgG:
IgG >Upper normal limit 1
>1.10 times ULN 2
Liver histology (evidence of hepatitis is a necessary condition)
Compatible with AIH 1
Typical AIH 2
Absence of viral hepatitis 2
Scoring Total:
>/=6: probable AIH
>/=7: definite AIH
*Addition of points achieved for all autoantibodies (maximum, 2 points).
Additional references on AIH criteria:
Scoring (points in bold):
if female gender, +2
if ALP: AST (or ALT) less than 1.5, then +2
if globulin >2 (+3), +2 if >15, +1 if >1
if ANA, >1:80 +3, 1:80 =2, 1:40 +1
if neg viral markers, +3
drug hx neg, +1
if alcohol <25g/d, +2
liver histology: if interface hepatitis +3, lymphoplasmacytic infiltrate +2
if autoimmunity in pt or 1st degree relative, then +2
if response to Rx, +2
Interpretation: if pretreatment >15 definite AIH, 10-15 probable
if posttreatment: >17 definite, 12-17 probable
Additional AIH references:
There is significant variability in the presentation of the most common inborn error of bile acid metabolism, 3β-hydroxy-Δ5-C27-steroid oxidoreductase (3β-HSD) deficiency (Molho-Pessach V et al, Hepatology 2012; 55: 1139-45).
This report investigated a 24-year-old women from Iran with idiopathic cirrhosis and a strong family history of idiopathic cirrhosis, as well as a 32-year-old first-cousin who had a self-limited liver disease (resolved at age 9). A genome-wide analysis of 2.4 million single nucleotide polymorphisms was performed in the patient and cousin and compared to a healthy relative. The investigators were able to identify regions of homozygosity that was present in the proband and cousin but not the healthy relative; one of these regions corresponded to a gene encoding 3β-HSD. Subsequent, sequence analysis revealed a specific frameshift mutation and high levels of 3β-hydroxy-Δ5 using mass spectrometry.
For me, this report has two take home points:
Additional references: